Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsNasopharyngeal CarcinomaOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU(400/250)/DOCE75/CISP100/FU700, Head and Neck Tumors, C1 (PID1348) -|- CETU250/CISP100/DOCE75/FU700, C2-3 (PID1349)CETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).CISP100/Radiation, Nasopharyngeal Ca, A (PID1714) -|- CISP80/FU1000, Nasopharyngeal Ca, B (PID1707)CRBP100/Radiation, Nasopharyngeal Ca, A (PID1781) -|- CRBP5/FU1000, Nasopharyngeal Ca, B (PID1782)DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750 - CISP40/Radiation, Nasopharyngeal Ca, A (PID1099) -|- B (PID1101)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)JUPITER-02: TORI240/CISP80/GEMC1000, Nasopharyngeal Ca (PID3012) -|- TORI240, Erh. (PID3013)PAED CISP100/FU1000, Nasopharyngeal Ca, A (PID723) -|- B (PID682) -|- C (PID738)PAED CRBP500/FU1000, Nasopharyngeal Ca, A (PID681) -|- B (PID682) -|- C (PID738)RATIONALE-309: TISL200/CISP80/GEMC1000, Nasopharyngeal Ca (PID2992) -|- TISL200, Erh. (PID2993)ChemotherapyChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelTislelizumabToripalimabChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelTislelizumabToripalimabChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelTislelizumabToripalimabChemo-substanceCapecitabineCarboplatinCetuximabCisplatinDocetaxelFluorouracilFolinic acidGemcitabineNivolumabOxaliplatinPaclitaxelTislelizumabToripalimabNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFolinic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSodium ThiosulfateNo. Substances1234567811Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAstheniaConstipationDiarrheaDysphagiaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaHeadacheHepatotoxicityHyperthyroidismHypokalemiaHypomagnesemiaHyponatremiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMucositisMyositisNail ChangesNauseaNephrotoxicityNeuropathyNeutropeniaOral MucositisOtotoxicityPneumoniaPruritusPyrexiaRadiation DermatitisRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorAdelstein DBuehrlen MChitapanarux IFerris RFrikha MFury MHaddad RLee ALee AWMMai HQMedina JAPatil VMSamlowski ESuntharalingam MSun YWanebo HWang FHYang YYou RZhang LDiseasefortgeschrittenes Nasopharynxkarzinom, T1-4N2-3M0, ECOG 0-2Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-, Erstlinie, ECOG 0-1Lokal fortgeschrittene Kopf-Hals-Tumoren, cT2 oder höher und N2–N3b nach AJCC 1997, ECOG 0-2lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes Nasopharynx-Ca, Tx und N2/N3 oder T3/T4 und Nx, ECOG 0-2Lokal fortgeschrittenes NasopharynxkarzinomLokal fortgeschrittenes Nasopharynxkarzinom Metastasiertes Nasopharynxkarzinom, CR oder PR nach 3 Zyklen Chemotherapie mit Cisplatin/5-FU, ECOG 0-2Nasopharynx-Ca, Stadium III-IVb, ECOG0-2Nasopharynxkarzinom, Stadium I - IV, unter 25 JahreNasopharynxkarzinom, Stadium III- IV, unter 25 JahreNasopharynxkarzinom, Stadium III - IV, unter 25 JahreNasopharynxkarzinom, Stadium III-IVB, Erstlinieneudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1Nicht resezierbares, rezidiviertes oder metastasiertes Nasopharynxkarzinom, ECOG 0-1rezidivierende oder metastasierte Kopf-Hals-Tumoren, Zweitlinie, ECOG 0-2rezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2wiederkehrender oder metastasierter Kopf-Hals-Tumor nach Platintherapiewiederkehrendes oder metastasiertes Nasopharynxkarzinom, nach Radiatio, ECOG 0-1OriginCancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of ChinaChiang Mai University, Chiang Mai, ThailandCleveland Clinic Foundation, ClevelandCollaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, ChinaDepartment of Clinical Oncology, The University of Hong Kong, NPC‐0501 trialDepartment of Medical Oncology, Dana Farber Cancer Institute, BostonDepartment of Medical Oncology of Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China, RATIONALE-309 trialDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New YorkDepartment of Pediatric and Adolescent Medicine, University Hospital Aachen, Germany, NPC-2003-GPOH/DCOGDepartment of Radiation Oncology, Sun Yatsen University Cancer Centre, ChinaDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Head and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsMedical Oncology department, University Hospital, Sfax (Tunisia), GORTEC 2006-02NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupOhio State University Comprehensive Cancer Center, Ohio State University, ColumbusServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainSun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, Guangzhou, JUPITER-02 trialSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ChinaTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversity of Utah Health Science Center, Salt Lake City, Utah, A Southwest Oncology GroupProtocols in Revision 31 protocols foundCarboplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1781 V1.0)Carboplatin 5 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1782 V1.0)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348 V1.3)Cetuximab 250 / Cisplatin 100 / Docetaxel 75 / Fluorouracil 700, Head and Neck Tumors, Cycle 2-3 (PID1349 V1.3)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244 V1.1)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621 V1.1)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622 V1.1)Cetuximab 500, Head and Neck Tumors (PID1241 V1.1)Cisplatin 100 / Capecitabine 1000, Nasopharyngeal Carcinoma (PID1784 V1.2)Cisplatin 100 / Fluorouracil 1000 / Radiation, Nasopharyngeal Carcinoma (PID1737 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334 V1.1)Cisplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1714 V1.1)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637 V1.1)Cisplatin 80 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1707 V1.1)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259 V1.0)Docetaxel 60 / Cisplatin 60 / Fluorouracil 600, Nasopharyngeal Carcinoma (PID1373 V1.1)Docetaxel 65 / Carboplatin 6, Head and Neck Tumors (PID1278 V1.0)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1099 V1.1)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part B (PID1101 V1.1)Gemcitabine 1000 / Cisplatin 80, Nasopharyngeal Carcinoma (PID1325 V1.1)Nivolumab 240, Head and Neck Tumors (PID856 V2.0)Oxaliplatin 70 / Radiation, Nasopharyngeal Carcinoma (PID1783 V1.0)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295 V1.1)PAED Carboplatin 500 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID681 V1.0)PAED Cisplatin 100 / Folinic Acid 25 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID723 V1.2)PAED Cisplatin 20 / Radiation, Nasopharyngeal Carcinoma, Part B (PID682 V1.1)Tislelizumab 200 / Cisplatin 80 / Gemcitabine 1000, Nasopharyngeal Carcinoma (PID2992 V1.0)Tislelizumab 200, Nasopharyngeal Carcinoma, maintenance (PID2993 V1.0)Toripalimab 240 / Cisplatin 80 / Gemcitabine 1000 - Toripalimab 240, Nasopharyngeal Carcinoma, maintenance (PID3013 V1.0)Toripalimab 240 / Cisplatin 80 / Gemcitabine 1000, Nasopharyngeal Carcinoma (PID3012 V1.0)Toripalimab 3, Nasopharyngeal Carcinoma (PID3014 V1.0)
